These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33276849)

  • 21. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convalescent plasma for COVID-19 considerations.
    Adiwinata Pawitan J
    Transfus Apher Sci; 2021 Feb; 60(1):102927. PubMed ID: 32878733
    [No Abstract]   [Full Text] [Related]  

  • 23. How did we rapidly implement a convalescent plasma program?
    Budhai A; Wu AA; Hall L; Strauss D; Paradiso S; Alberigo J; Hillyer CD; Jett B; Tobian AAR; Bloch EM; Sachais BS; Shaz BH
    Transfusion; 2020 Jul; 60(7):1348-1355. PubMed ID: 32449169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan.
    Hassan MO; Osman AA; Elbasit HEA; Hassan HE; Rufai H; Satti MMM; Elnegoumi M; Idris R; Musa A; Ali AH; Zroog SA; Altayb ADA; Khairy A; Allam M; Abdelhalim ATI
    Transfus Apher Sci; 2020 Dec; 59(6):102918. PubMed ID: 32900597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 26. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
    Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
    Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.
    Pal P; Ibrahim M; Niu A; Zwezdaryk KJ; Tatje E; Robinson WR; Ko L; Satyavarapu I; Jones WE; Nachabe A; Luk A; Mushatt DM; Halvorson K; Denson JL; Smith CC; Simeone F; Davis G; Gill SK; McDougal A; Vigh AS; Peterson TG; Ning B; Hu T; Socola F; Robinson J; Safah H; Saba NS
    Transfus Med; 2021 Jun; 31(3):217-220. PubMed ID: 33073895
    [No Abstract]   [Full Text] [Related]  

  • 31. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
    Joob B; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
    [No Abstract]   [Full Text] [Related]  

  • 32. [COVID-19: blood sufficiency versus convalescent plasma?].
    Contreras M
    Rev Med Chil; 2020 Jun; 148(6):721-723. PubMed ID: 33480368
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of Convalescent Plasma in the Management of COVID-19.
    Dandachi D; Khalaf SA
    Mo Med; 2021; 118(2):118. PubMed ID: 33840851
    [No Abstract]   [Full Text] [Related]  

  • 34. Convalescent plasma therapy in patients with COVID-19.
    Altuntas F; Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Turgut B; Erkurt MA
    Transfus Apher Sci; 2021 Feb; 60(1):103017. PubMed ID: 33277207
    [No Abstract]   [Full Text] [Related]  

  • 35. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic Effect of Convalescent Plasma Transfusion on Fulminant Viral Infectious Diseases--Review].
    Wang HR; Liu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):988-992. PubMed ID: 34105505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Convalescent plasma (CP) therapy in patients with COVID-19.
    Cakir B
    Transfus Apher Sci; 2021 Feb; 60(1):103018. PubMed ID: 33257204
    [No Abstract]   [Full Text] [Related]  

  • 39. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.
    Mira E; Yarce OA; Ortega C; Fernández S; Pascual NM; Gómez C; Alvarez MA; Molina IJ; Lama R; Santamaria M
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2793-2795. PubMed ID: 32652231
    [No Abstract]   [Full Text] [Related]  

  • 40. [Convalescent plasma therapy in COVID-19 patients].
    Ascencios L; Casa L
    Medicina (B Aires); 2021; 81(2):306. PubMed ID: 33906156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.